Is Cell Source, Inc. (CLCS) a Buy, Sell, or Hold?
Cell Source, Inc.
OTC:CLCS
$0.75 USD
-$0.2 (-21.05%)
- Volume
- 4K
- Average Volume
- 2.63K
- Market Capitalization
- $33.78M
- P/E Ratio
- -7.50
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $2.25
- Year Low
- $0.28
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.02
Industry, Sector & symbol
| Stock Exchange | OTC |
| CEO | Itamar Shimrat |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CLCS |
| CUSIP | 15114L104 |
| CIK | 0001569340 |
| Web | https://www.cell-source.com |
| Phone | 646 416 7896 |
| Currency | USD |
| Employees | 1 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -0.58 |
| Payout Ratio | 0.00 |
| Current Ratio | 0.02 |
| Quick Ratio | 0.02 |
| Cash Ratio | 0.02 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -0.05 |
| Price / Cash Flow | -12.37 |
| Price / Book | -1.82 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 0 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.1 |
| Trailing P/E Ratio | -7.50 |
| PEG Ratio | -1.40 |
| P/E Growth | -1.40 |
| Net Income | $-4.64M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | 22.48% |
| Return on Assets | -999.35% |
Financials Score
| AltmanZ Score | -358.92 |
| Piotroski Score | 2.00 |
| Working Capital | -18.8M |
| Total Assets | 286.5K |
| Ebit | -4.74M |
| Market Cap | 42.79M |
| Total Liabilities | 19.08M |
Poll Results
About Cell Source, Inc. (OTC:CLCS) Stock
Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based therapies centered on regulating immune tolerance. The company's flagship innovation is its Veto Cell immune system management technology, an advanced immune tolerance platform capable of selectively suppressing specific immune responses. This Veto Cell technology finds application in numerous areas, including enhancing the acceptance of stem cell transplants for conditions like lymphoma, leukemia, and multiple myeloma. Furthermore, it is utilized in treating end-stage kidney disease, various other non-malignant organ diseases, and a spectrum of both cancerous and non-malignant illnesses. Founded in 2012, Cell Source, Inc. maintains its corporate headquarters in New York, New York. ...
2026-05-21 09:00:00
Plans to expand clinical program and uplist to the NASDAQ were also presented. NEW YORK, NY / ACCESS Newswire / May 21, 2026 / Cell Source, Inc. (OTC PINK:CLCS) ("Cell Source" or the "Company"), a leading innovator in immune tolerance management, recently presented its plans to expand its clinical program for haploidentical (partially mismatched donor) stem cell (e.g.
Cell Source, Inc. to Present at the LD Micro Invitational XVI
2026-05-14 16:00:00
New York, New York--(Newsfile Corp. - May 14, 2026) - Cell Source, Inc. (OTC Pink: CLCS) announced today that it will be participating in the 16th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel in Los Angeles, CA May 18th and 19th, 2026. Cell Source, Inc. is scheduled to present on Monday, May 18, 2026 at 02:30 PM.
Frequently Asked Questions
-
What is the current Cell Source, Inc. (CLCS) stock price?
-
Cell Source, Inc.(OTC:CLCS) stock price is $0.75 in the last trading session. During the trading session, CLCS stock reached the peak price of $2.25 while $0.28 was the lowest point it dropped to. The percentage change in CLCS stock occurred in the recent session was --21.05% while the dollar amount for the price change in CLCS stock was -$-0.2.
-
CLCS's industry and sector of operation?
-
The OTC listed CLCS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CLCS?
-
Dennis Brown | Executive Chairman
Itamar Shimrat | Chief Executive Officer, President & Chief Financial Officer
|
|
| -
How many employees does CLCS have?
-
Number of CLCS employees currently stands at 1. CLCS operates from 57 West 57th Street, New York City, NY 10019, US.
-
Link for CLCS official website?
-
Official Website of CLCS is: https://www.cell-source.com
-
How do I contact CLCS?
-
CLCS could be contacted at phone #646 416 7896 and can also be accessed through its website. CLCS operates from 57 West 57th Street, New York City, NY 10019, US.
-
How many shares of CLCS are traded daily?
-
The average number of CLCS shares traded daily for last 3 months was 2.63K.
-
What is the market cap of CLCS currently?
-
The market value of CLCS currently stands at $33.78M with its latest stock price at $0.75